The INSPECTOR study: enhanced feasibility for clinical translation of a multi‐cancer early detection method based on enzyme‐assisted high signal‐to‐noise ratio sequencing of methylated circulating tumor DNA
Cancer Communications · 2025
DOI: 10.1002/cac2.70071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, 2025. Verfasst von Hui-Yan Luo und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. Hauptthemen laut MEDLINE: DNA Methylation, Early Detection of Cancer, Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Blood‐based cell‐free DNA (cfDNA) methylation testing has emerged as a promising approach for multi‐cancer early detection (MCED), holding the potential to improve cancer survival rates. However, traditional bisulfite‐based methods often encounter sensitivity limitations in detecting early‐stage malignancies or certain cancer types. In the INSPECTOR study, we developed a MCED and cancer signal origin (CSO) system specifically designed for early‐stage or hard‐to‐detect cancers, including those of the lung, breast, colorectum, liver, esophagus, stomach, pancreas, and ovary.
Methods
We established a comprehensive methylation marker discovery database ( n = 6,342) by integrating public datasets ( n = 4,699) and in‐house samples ( n = 1,643), all processed using human TET (hTET) enzyme‐assisted whole‐methylome sequencing (GM‐seq). This enabled the design of a targeted panel encompassing 155,362 methylated CpG sites. Leveraging hTET‐assisted high‐depth next‐generation sequencing (NGS), our blood test achieved a median unique depth of 1,093×. Multicenter case‐control cohorts, including various pathological subtypes, were used for training, validation, and independent validation of MCED and CSO models, and to verify the clinical feasibility.
Results
Clinical validation was conducted across multi‐center case‐control cohorts, including 1,071 participants in the training set, 581 in the validation set, and 824 in the independent validation set. The MCED assay demonstrated robust performance with a specificity of 99.1% and sensitivity of 83.2% in the training set, 99.0% and 81.8% in the validation set, and comparable results in the independent validation set (99.0% specificity, 81.9% sensitivity). Notably, sensitivity reached 65.5% for stage I cancers, 79.7% for stage II, and 71.3% for stages I‐II combined. The sensitivities for different cancer types were as follows: esophageal (79.2%), gastric (76.1%), colorectal (86.2%), pancreatic (66.7%), liver (100.0%), lung (72.9%), breast (88.9%), and ovarian (87.9%). The CSO model exhibited strong accuracy, with top‐1 cancer origin prediction rates of 87.9% (validation) and 87.4% (independent validation), rising to 95.1% and 94.5% for top‐2 predictions, respectively. For stage I cancers specifically, the top‐1 accuracy was 85.5%.
Conclusions
These findings underscore the efficacy of the hTET‐assisted cfDNA methylation sequencing system across diverse cancer types, particularly in early stages. Enzyme‐assisted NGS test of methylated cfDNA thus enhances the clinical utility of non‐invasive blood‐based screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
- Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
- Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
- Department of Liver Surgery, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, P. R. China.
- Department of Early Cancer Screening Research and Development, GenePlus-Beijing Institute, Beijing, P. R. China.
- Department of Research and Experimental, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
ORCID-Profile: Hui-Yan Luo, Hai-Bo Qiu, Yuan-Fang Li, Zhi-Wei Zhou, Rong-Ping Guo, Xin Huang, Mian Xi, Qiang Zeng, Rui-Hua Xu
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Science and Technology Program of Guangzhou
- Guangdong Special Support Plan
- Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
- Young Talents Program of Sun Yat-sen University Cancer Center
- CAMS Innovation Fund for Medical Science
Zitieren
APA
Luo, H. Y., Wei, W., Li, P., Zhang, Q. H., Zhou, Z., Cui, L., Lin, Y. B., Yang, H., Zhong, X., Liu, Q., Yang, H., Luo, K. J., Qiu, H. B., Yuan, S. Q., Li, Y. F., Zhou, Z. W., Lin, X. J., Cui, B. K., Zhang, R. X., …, & Xu, R. H. (2025). The INSPECTOR study: enhanced feasibility for clinical translation of a multi‐cancer early detection method based on enzyme‐assisted high signal‐to‐noise ratio sequencing of methylated circulating tumor DNA. Cancer Communications. https://doi.org/10.1002/cac2.70071
Vancouver
Luo HY, Wei W, Li P, Zhang QH, Zhou Z, Cui L, et al. The INSPECTOR study: enhanced feasibility for clinical translation of a multi‐cancer early detection method based on enzyme‐assisted high signal‐to‐noise ratio sequencing of methylated circulating tumor DNA. Cancer Communications. 2025. doi:10.1002/cac2.70071
BibTeX
@article{Luo2025,
author = {Luo, Hui-Yan and Wei, Wei and Li, Pansong and Zhang, Qi-Hua and Zhou, Zhipeng and Cui, Liang and Lin, Yong-Bin and Yang, Hong and Zhong, Xianyu and Liu, Qingfeng and Yang, Han and Luo, Kong-Jia and Qiu, Hai-Bo and Yuan, Shu-Qiang and Li, Yuan-Fang and Zhou, Zhi-Wei and Lin, Xiao-Jun and Cui, Bo-Kang and Zhang, Rong-Xin and Fan, Wen-Hua and Huang, He and Lan, Chun-Yan and Li, Jun-Dong and Wang, Zhi-Qiang and Li, Bin-Kui and Guo, Rong-Ping and Tang, Jun and Huang, Xin and Xi, Mian and Liu, Yuying and Xie, Chuanbo and Chen, Shi and Li, Zhi-Hu and Liu, Yu-Hua and Zhang, Xiao-Ting and Zeng, Qiang and Yi, Xin and Xu, Rui-Hua},
title = {The INSPECTOR study: enhanced feasibility for clinical translation of a multi‐cancer early detection method based on enzyme‐assisted high signal‐to‐noise ratio sequencing of methylated circulating tumor DNA},
journal = {Cancer Communications},
year = {2025},
doi = {10.1002/cac2.70071}
}
EUVIMED